Biotech / Finance

Amgen's Repatha Results Not Good Enough For The Street

From Biotech
March 17, 2017 - 9:42am
Shares of Amgen, Inc. (NASDAQ: AMGN) fell 7 percent after the biotechnology company released data from its therapy called Repatha, which is used to lower the risk of heart attacks, strokes and heart problems. Amgen reported Repatha reduces the risk of heart attacks, stokes and other heart-related health problems. However, investors weren't enthusiastic as the company's report said "there were no notable differences seen between treatment arms in the overall rate of adverse events, serious adverse events or adverse events leading to study drug discontinuation." TheStreet's Adam Feuerstein commented that Repatha's success in reducing the ...Full story available on Benzinga.com


Continue reading this article »